Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions: Comparison of Epidemiological and Therapeutic Aspects with Deferoxamine

Author： Kontoghiorghes G.J.   Neocleous K.   Kolnagou A.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.26, Iss.8, 2003-01, pp. : 553-584

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Deferiprone vs deferoxamine in thalassaemia

By  

Inpharma, Vol. 1, Iss. 1352, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Deferasirox dominates deferoxamine for iron overload

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 665, 2012-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations

By  

Current Medicinal Chemistry, Vol. 12, Iss. 23, 2005-11 ,pp. : 2663-2681

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia: Impact of Splenectomy and Iron Status

By >  

Clinical Pharmacokinetics, Vol. 50, Iss. 1, 2011-01 ,pp. : 41-50

Adis International

Access to resources Recommend Favorite

A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis

By Gonsette Richard E  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 747-765

Informa Healthcare

Access to resources Recommend Favorite